FDA Indication for Use: ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration as an aid in monitoring progression of disease factors causing metamorphopsia including, but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation. ForeseeHome is not intended to diagnose; diagnosis is the responsibility of the prescribing eye-care professional.
The ForeseeHome AMD Monitoring Program is prescription use only and is intended to be used as in addition to regular eye exams.
ForeseeHome is a registered trademark, and the ForeseeHome AMD Monitoring Program and logo and the Notal Vision logo are trademarks of Notal Vision.
The technical component of the ForeseeHome AMD Monitoring Program is covered by Medicare, subject to its coverage requirements for the test, to assess patients with Dry AMD who are at risk of developing Wet AMD.
Please refer to your local Medicare Administrative Contractor (MAC) for which the ordering physician resides concerning coverage availability for the physician professional services component of the test.
© 2017 Notal Vision™ , Inc. All rights reserved.